NCT04868500 is a NA clinical trial of AMAZE™ Application in Asthma, sponsored by AstraZeneca.

Who is sponsoring NCT04868500?

NCT04868500 is sponsored by AstraZeneca.

What drugs are being tested in NCT04868500?

Interventions in NCT04868500: AMAZE™ Application, AMAZE™ Dashboard.

Is NCT04868500 still recruiting?

NCT04868500 is currently completed. Last updated 8 February 2023.

Are results published for NCT04868500?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-08 · How we verify

NCT04868500

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

Completed NA Results posted Last updated 8 February 2023

What this trial tests

NA trial testing AMAZE™ Application in Asthma in 49 participants. Completed in 30 November 2021.

Timeline

27 April 2021

Primary endpoint
30 November 2021

30 November 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	49
Start date	27 April 2021
Primary completion	30 November 2021
Estimated completion	30 November 2021
Sites	1 location across United States

Drugs / interventions tested

AMAZE™ Application
AMAZE™ Dashboard

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Days Participants Accessed the AMAZE™ App (Weeks 1 to 4) Primary · Weeks 1 to 4

Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 1 to 4.

Home

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	16.8	± 7.1

Daily asthma log

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	16.5	± 6.8

Air quality

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	2.3	± 1.5

My plan

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	2.2	± 1.5

Trends

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	2.8	± 3.0

Appointments

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.3	± 0.5

Educational material

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± 0.0

Messages

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	2.3	± 2.4

Number of Days Participants Accessed the AMAZE™ App (Weeks 5 to 8) Primary · Weeks 5 to 8

Home

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	12.5	± 8.6

Daily asthma log

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	12.1	± 8.6

Air quality

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.5	± 0.7

My plan

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.6	± 0.8

Trends

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.6	± 0.8

Appointments

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.3	± 0.5

Educational material

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± 0.0

Messages

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.8	± 1.5

Number of Days Participants Accessed the AMAZE™ App (Weeks 9 to 12) Primary · Weeks 9 to 12

Home

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	11.4	± 8.1

Daily asthma log

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	11.2	± 7.8

Air quality

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± 0.0

My plan

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.5	± 1.0

Trends

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.4	± 0.5

Appointments

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.3	± 0.6

Educational material

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± NA

Messages

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.4	± 0.5

Number of Days Participants Accessed the AMAZE™ App (Weeks 13 to 16) Primary · Weeks 13 to 16

Home

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	12.6	± 8.2

Daily asthma log

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	12.1	± 8.1

Air quality

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± 0.0

My plan

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.1	± 0.3

Trends

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.1	± 0.3

Appointments

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.2	± 0.4

Educational material

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± 0.0

Messages

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.3	± 0.6

Number of Days Participants Accessed the AMAZE™ App (Weeks 17 to 20) Primary · Weeks 17 to 20

Home

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	9.3	± 7.5

Daily asthma log

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	8.9	± 7.2

Air quality

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± NA

My plan

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.2	± 0.4

Trends

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.2	± 0.4

Appointments

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.5	± 0.7

Educational material

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± NA

Messages

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.3	± 0.8

Number of Days Participants Accessed the AMAZE™ App (Weeks 21 to 24) Primary · Weeks 21 to 24

Home

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	7.6	± 7.2

Daily asthma log

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	7.8	± 7.3

My plan

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.2	± 0.4

Trends

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.0	± 0.0

Appointments

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	3.0	± NA

Messages

Group	Value	95% CI
Massachusetts General Hospital (MGH) Participants	1.3	± 0.5

Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 1 to 4) Primary · Weeks 1 to 4

Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 1 to 4.

Group	Value	95% CI
Massachusetts General Hospital (MGH) Clinical Site Staff	8.3	± 6.7

Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 5 to 8) Primary · Weeks 5 to 8

Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 5 to 8.

Group	Value	95% CI
Massachusetts General Hospital (MGH) Clinical Site Staff	5.8	± 6.1

Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 9 to 12) Primary · Weeks 9 to 12

Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 9 to 12.

Group	Value	95% CI
Massachusetts General Hospital (MGH) Clinical Site Staff	6.6	± 6.1

Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 13 to 16) Primary · Weeks 13 to 16

Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 13 to 16.

Group	Value	95% CI
Massachusetts General Hospital (MGH) Clinical Site Staff	5.8	± 6.5

Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 17 to 20) Primary · Weeks 17 to 20

Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 17 to 20.

Group	Value	95% CI
Massachusetts General Hospital (MGH) Clinical Site Staff	5.6	± 6.5

Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 21 to 24) Primary · Weeks 21 to 24

Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 21 to 24.

Group	Value	95% CI
Massachusetts General Hospital (MGH) Clinical Site Staff	6.7	± 4.9

Sponsor's own description

The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Observational study of the Amaze™ asthma disease management platform.
Alladina J, Moschovis PP, Gandhi HN, Carstens D, et al · · 2024 · cited 2× · PMID 39479373 · DOI 10.1177/20552076241282380

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04868500 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04868500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04868500

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Asthma

Other AstraZeneca trials

Verify against primary sources